DrugRisk Update: Diabetes Expert Warns of Byetta Cancer Risk
DrugRisk is the Web´s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com
Los Angeles, CA (PRWEB) June 06, 2013
The diabetes drug safety center at DrugRisk.com is announcing updated information for patients taking the medication Byetta. A university head of endocrinology and former editor of the American Diabetes Association journal has advised the drug may be connected to pancreatic cancer*.
DrugRisk was created to improve the safety of patients taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Byetta is a twice-daily injectable medication released in 2005 to help those with type-2 diabetes control blood sugar. Last year the drug had sales of over $300 million, when it was acquired by Bristol-Myers Squibb**.
The resource center added a 2011 study from the University of California at Los Angeles, indicating Byetta could increase the risk of pancreatic cancer by 290% and thyroid cancer by 473%***.
Now, DrugRisk has learned that the lead researcher of that study, head of endocrinology at UCLA Dr. Peter Butler, worries that the risk was not detected in trials prior to FDA approval because the manufacturer used very young animals not as prone to pancreatic cancer*.
The FDA has also announced it is investigating the risk of Byetta cancer after receiving reports that some patients who died showed signs of early pancreatic cancer cells****.
Due to the number of patients filing a Byetta lawsuit alleging cancer, lawyers have asked that cases be consolidated to a special federal multi-district court in California. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).
Anyone affected by cancer after taking Byetta is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Byetta lawsuits.
*New York Times, 5/31/13; nytimes.com/2013/05/31/business/a-doctor-raises-questions-about-a-diabetes-drug.html?hp&_r=1&
**Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
***Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
****FDA, 3/14/13; http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebbyetta-side-effects/resource-center/prweb10807087.htm